AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200 mg every 3 weeks
Study NCT04551521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: 9 mg once daily
Study NCT05081180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive intravenous infusion at a flat dose or weight based dose of Avelumab, every 2 weeks (Q2W) until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when Maximum tolerated dose (MTD) and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
Study NCT05081180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants with primary CNS malignancies who have received at least 1 prior therapy will be enrolled into Dose Escalation Part 1 and will receive daily oral escalated dose level of Lenvatinib until progression, unacceptable toxicity, or withdrawal of consent. Enrollment into part 1 of the study will end when MTD and/or a safe Recommended Dose for Expansion (RDE) for the expansion cohort is determined. Participants with defined CNS tumors will be enrolled into Dose Expansion Part 2 and will receive RDE of Lenvatinib in Part 2 until progression, unacceptable toxicity, or withdrawal of consent.
Study NCT06554444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Implant Surgery
Description: Dental implants will be placed in edentulous areas.
Study NCT06259448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine self-sampling
Description: urine self-sampling
Study NCT06189313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleaner Pro Thrombectomy System
Description: The Cleaner™ Pro Thrombectomy System (Cleaner Pro) is a catheter-based aspiration thrombectomy device comprised of a handpiece, an aspiration catheter, a dilator, and an aspiration canister.
Study NCT06644066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial pressure of Oxygen Control method
Description: During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06325683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Given PO
Study NCT05720715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A 0.05% eye drops
Description: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.
Study NCT05720715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclosporine A 0.05% eye drops
Description: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06325683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06325683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT06325683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT05664763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPEB with PET
Description: radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
Study NCT05664763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cannabis abstinence
Description: Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
Study NCT04650269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50Mg-200Mg-25Mg Tablet
Description: Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
Study NCT04650269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV care
Description: HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.
Study NCT06439225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 q21 days
Study NCT06439225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 q21 days
Study NCT06439225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 q21 days
Study NCT06189963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
Study NCT06189963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Lactate Hartmann's Solution
Study NCT06037369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: customized standardized educational program sent by LINE software.
Description: At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
Study NCT06081595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib 100mg bid
Study NCT04954001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-159
Description: FCN-159 is administered orally in once daily schedule for 28 days a cycle.
Study NCT05197530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
Study NCT05197530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSpectral Imaging System
Description: Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
Study NCT04684459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual-targeting HER2 and PD-L1 CAR-T cells
Description: HER2-positive solid tumor serosal cavity infusion
Study NCT06081595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 375mg qd
Study NCT06524375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered as per the schedule specified in the arm.
Study NCT06524375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cBTKi Monotherapy
Description: Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
Study NCT06569667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRC supported text + AI driven SDH-enhanced text
Description: This interventional study evaluates an AI-driven texting tool combined with peer recovery coach support to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
Study NCT06569667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI driven SDH-enhanced text only
Description: This interventional study evaluates an AI-driven SDH-enhanced texting tool to deliver social services, reduce stigma, and provide patient navigation content. The goal is to enhance the receipt of buprenorphine in primary care among emergency department-enrolled Black and Latinx individuals who use opioids, addressing the disproportionate impact of opioid overdose deaths on these communities.
Study NCT06569667 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Control Arm-3 will receive treatment as usual (i.e., verbal instructions, NYC Dept of Health pamphlets detailing access to OUD and social services, health system smartphone application EMR patient portal).
Study NCT05892991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential current
Description: this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
Study NCT05892991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interferential current
Description: this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
Study NCT06362252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration
Study NCT06362252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous administration
Study NCT06362252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration
Study NCT04807972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion
Study NCT04807972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budiglimab
Description: Intravenous (IV) Infusion
Study NCT04807972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX
Description: Intravenous (IV) Infusion
Study NCT04231760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Study NCT04231760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Study NCT04231760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study NCT04231760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Study NCT06412133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: photography
Description: This study examines the impact of phototherapy intervention on anxiety, stress, and body image among breast cancer patients. Participants engaged in a five-week, one-on-one session series, utilizing a pre-post-test design with parallel groups.
Study NCT06121869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will supplement daily for 10 weeks with 2 grams rice flower placebo in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
Study NCT06121869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine
Description: Participants will supplement daily for 10 weeks with 2 grams leucine in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
Study NCT06121869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dileucine
Description: Participants will supplement daily for 10 weeks with 2 grams dileucine (RAMPS, Ingenious Ingredients, TX, USA) in capsule form. On training days, participants will consume their assigned supplement within 60 minutes of completing their workout. On non-training days, participants will consume their assigned supplement with their first meal of the day. All doses will be consumed with 8-12 ounces of water.
Study NCT05128188 — intervention group
Intervention type: OTHER
Intervention: No intervention will be given in this study
Description: No intervention will be given in this study
Study NCT05496075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
Study NCT05496075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat placebo
Description: Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.
Study NCT05551078 — intervention group
Intervention type: BIOLOGICAL
Intervention: thrombophilia screening
Description: In the IUGR group systematic thrombophilia screening had already been performed.
Study NCT05336084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultradian sleep/wake protocol
Description: 120-minute schedule, consisting of 80 minutes awake followed by a 40 minute sleep opportunity for 36 hours
Study NCT06375928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study NCT06375928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study NCT06375928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metallic stent (SEMS)
Description: Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm.
Study NCT06375928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct > 18mm.~* DPPS size: 7Fr x 3-7cm.
Study NCT04792255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid artery stenting with standard contrast media protocol
Description: Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
Study NCT04792255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with reduced contrast media protocol
Description: Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
Study NCT04792255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid Duplex Ultrasound
Description: Pre- and postinterventional assessment of the treated internal carotid artery.
Study NCT04792255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Duplex Ultrasound
Description: Pre- and postinterventional assessment of the treated internal carotid artery.
Study NCT06331533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Intradermal botulinum toxin A was applied to the treatment side
Study NCT06331533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl was injected into the placebo side
Study NCT04892459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
Study NCT04892459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study NCT05670795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Follicle Stimulating Hormone
Description: clinical pregnancy rates
Study NCT05670795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone and Clomiphene Citrate
Description: clinical pregnancy rates
Study NCT06170658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses
Description: Daily disposable, silicone hydrogel investigational lenses for one week
Study NCT06510725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mutitarget tDCS
Description: Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.
Study NCT06510725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-target tDCS
Description: Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.
Study NCT06510725 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
Study NCT06170658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses
Description: Daily disposable, hydrogel commercially available lenses for one week